News & Events

News

Nexstim offers targeted and effective therapies and diagnostics for challenging brain diseases and disorders. Our technology is solidly grounded in scientific and clinical research. We closely collaborate with key opinion leaders who, like us, believe noninvasive brain stimulation harnesses the brain's own healing power—neuroplasticity. Nexstim is helping patients—and their families—get back the life they feared they had lost.

Customers and Trade

Research and Development

Nexstim NBT® System with SmartFocus® TMS installed at Mind Matters PsychiatryMD, US

Nexstim Plc‘s Technology Licencing Discussions Ended with a Leading California Based Academic Institution

Nexstim Plc’s Financial Information in 2020

Nexstim Plc’s Board of Directors resolved on a directed share issue of approximately 141 thousand euro to Kreos Capital V (UK) Limited

Nexstim Plc: Health Canada Grants Nexstim NBT® Medical Device License for Canada

Nexstim NBT® System with SmartFocus® TMS installed at Rockford Psychiatric Medical Services, US

Nexstim has received four new NBS System orders in October-November

Nexstim Plc: Shares subscribed for in the directed share issue have been registered

Nexstim Plc: In total 15,687,350 shares subscribed in the directed share issue

Nexstim Plc has decided on a directed share issue of approximately EUR 1.8 million based on authorization of the Extraordinary General Meeting of Shareholders

Dr. Leena Niemistö starts as new Chair of the Board of Nexstim Plc

Nexstim Plc: Decisions of the Extraordinary General Meeting of Shareholders